Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bufo gargarizans

ABSTRACT: Bufo gargarizans overview

PROVIDER: PRJNA258481 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR11637930_1.fastq.gz	Fastqsanger.gz
	SRR11637930_2.fastq.gz	Fastqsanger.gz
	SRR11637931_1.fastq.gz	Fastqsanger.gz
	SRR11637931_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 65

Similar Datasets

Bufo gargarizans

Project description:Bufo gargarizans transplant

| PRJNA383934 | ENA

Bufo gargarizans

Project description:Bufo gargarizans Raw sequence reads

| PRJNA378697 | ENA

Bufo gargarizans

Project description:Bufo gargarizans Raw sequence reads

| PRJNA853591 | ENA

Bufo gargarizans strain:Cantor

Project description:Bufo gargarizans strain:Cantor Transcriptome or Gene expression

| PRJNA258419 | ENA

Bufo gargarizans isolate:SCDJY-AF-19

Project description:Bufo gargarizans isolate:SCDJY-AF-19 Genome sequencing and assembly

| PRJNA628553 | ENA

Bufo bufo

Project description:Bufo bufo overview

| PRJNA693960 | ENA

Bufo gargarizans andrewsi

Project description:Bufo andrewsi raw genome sequence reads

| PRJNA283182 | ENA

Bufo bufo

Project description:Transcriptome of common toad, Bufo bufo

| PRJNA769252 | ENA

Project description:Bufo gargarizans mitochondrion

| PRJNA1235100 | ENA

Structurally diverse bufadienolides from the skins of Bufo bufo gargarizans and their cytotoxicity.

Project description:Natural products, with their extensive chemical diversity, distinctive biological activities, and vast reservoirs, provide a robust foundation for advancing cancer therapeutics. A comprehensive phytochemical investigation of the skins from Bufo bufo gargarizans afforded two new bufadienolide derivatives identified as bufalactamides A and B (1-2), along with six known compounds: argentinogenin (3), desacetylcinobufagin (4), desacetylcinobufaginol (5), cinobufaginol (6), bufalin (7) and gamabufalin (8). The structural elucidation of these compounds was meticulously carried out by analyses of spectroscopic data (1D and 2D NMR, HR-ESIMS), and comparison with the literature data. Plausible biosynthetic pathways for the new compounds were also discussed. Moreover, the cytotoxicity of the compounds was investigated using various cancer cell lines, including lung cancer (A549), colon cancer (HCT-116), liver cancer (SK-Hep-1), and ovarian cancer (SKOV3). Our research findings indicated that compounds 3, and 6-8 exhibit potent cytotoxic activity (IC50 < 2.5 µM). In contrast, compounds 4 and 5 display moderate cytotoxic activity (IC50 < 50 µM) while compounds 1 and 2 show no cytotoxic activity (IC50 > 100 µM). From this data, we conducted a comprehensive analysis of the structure-activity relationships among these compounds.

| S-EPMC11550443 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data